Mesothelioma drug trial halted early – what we know
NCT ID NCT02863055
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested whether the drug nintedanib could help people with malignant pleural mesothelioma keep their cancer from growing after initial chemotherapy. 37 patients were randomly assigned to receive either nintedanib or a placebo twice daily. The study was terminated early, so its findings are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Nintedanib
What this could lead to
If successful, nintedanib could offer a way to delay cancer progression in mesothelioma patients after initial chemotherapy.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. Nintedanib may not improve outcomes and can cause side effects like diarrhea or liver issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT PLEURAL MESOTHELIOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Manchester University NHS Foundation Trust - UHSM-Wythenshawe Hospital
Wythenshawe, Manchester, M23 9LT, United Kingdom
-
NHS South Tyneside-South Tyneside District Hospital
South Shields, United Kingdom
-
Ospedale San Paolo
Milan, Italy
-
Royal Marsden Hospital
Chelsea, United Kingdom
-
Royal Marsden Hospital
Sutton, United Kingdom
-
Royal Marsden Hospital - Kingston
Kingston, United Kingdom
-
Sheffield Teaching Hospitals NHS Foundation Trust - Weston Park Hospital
Sheffield, United Kingdom
-
UZ Antwerpen
Antwerp, Belgium
-
UZ Gent
Ghent, Belgium